Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$295.90 ▼ -36.39
(-10.95%)
MKT CAP: $9.84B • VOL: 1.20M
52W L $184 52W H $383
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$249
MEDIAN
$331
MEAN
$337
HIGH
$402
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KRYS TAPE
KRYS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $358.04 | $340.28 | 2025-02-14 | $269.27 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $372.83 | $349.16 | 2025-02-06 | $278.15 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $337.33 | $325.49 | 2025-01-29 | $284.06 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $301.82 | — | 2025-01-17 | $289.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $260.39 | $281.10 | 2025-01-09 | $263.35 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $352.12 | $307.74 | 2024-12-18 | $257.43 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $287.02 | $298.86 | 2024-12-04 | $275.19 | -4.3% | 48% | C |